Charter Medical, INCELL Announce Distribution Agreement
The partnership provides Charter Medical the exclusive rights to market, sell, and distribute INCELL media products on a global basis.
Charter Medical Ltd., a manufacturer of products for the regenerative medicine and bioprocessing industries announced a partnership with INCELL Corporation that provides Charter Medical the exclusive rights to market, sell, and distribute INCELL media products on a global basis. INCELL develops and manufactures specialty medias and formulated solutions for tissue and cell collection, transport, processing, and storage.
The partnership will enable both organizations to meet the growing customer demand for more comprehensive solutions in cell culture, cell expansion, and cryopreservation, Charter Media reported in a press release.
Source: Charter Medical
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
